Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Intelligent Bio Solutions Inc. (NASDAQ: INBS) Closes $10M Private Offering Amid Investor Interest By: AB Newswire March 13, 2024 at 14:52 PM EDT Intelligent Bio Solutions Inc. (NASDAQ: INBS) the medical technology firm, renowned for its provision of rapid, non-invasive, and intelligent testing solutions, revealed that it had executed several securities purchase agreements on March 8, 2024, and declared the conclusion of the $10.1M offering on March 12, 2024. Currently, the stock of Intelligent Bio Solutions is trading above its 10, 20, and 50-day moving averages, having experienced a surge of approximately 65% in the last month and 37% since January 1, 2024. This surge occurred on relatively low trading volume compared to its 30- and 60-day volume averages. It's important to highlight that the stock has an extremely low reported float and is trading around $4.50 per share, with a 52-week high of $49.20 per share. Furthermore, institutional investors own approximately 9.3% of Intelligent Bio Solutions shares, while insiders hold 0.3%. See Institutional Ownership Information The company disclosed that these agreements were with various institutional and accredited investors. Intelligent Bio Solutions issued a total of 2,223,333 shares of common stock, along with Series H-1 warrants for the purchase of up to 2,223,333 shares of common stock, and Series H-2 warrants for the purchase of 2,223,333 shares of common stock. The shares were priced at $4.55 each, aiming to raise approximately $10.1 million in proceeds. However, it's important to note that deductions for agent fees and other offering-related expenses will be applied. Additionally, Intelligent Bio Solutions announced that the Series H-1 warrants would have an 18-month term, while the Series H-2 warrants would be valid for 5 years. Ladenburg Thalmann & Co., Inc. serves as the exclusive agent for the private placement, expected to close by March 12, 2024. The proceeds from the offering will be allocated towards financing the company's general corporate and working capital requirements. Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content."TSR" is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. "TSR" authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. "TSR" has not been compensated to produce content related to "Any Companies" appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.Media ContactCompany Name: The Street ReportsContact Person: EditorEmail: Send EmailCountry: United StatesWebsite: http://www.thestreetreports.com Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Intelligent Bio Solutions Inc. (NASDAQ: INBS) Closes $10M Private Offering Amid Investor Interest By: AB Newswire March 13, 2024 at 14:52 PM EDT Intelligent Bio Solutions Inc. (NASDAQ: INBS) the medical technology firm, renowned for its provision of rapid, non-invasive, and intelligent testing solutions, revealed that it had executed several securities purchase agreements on March 8, 2024, and declared the conclusion of the $10.1M offering on March 12, 2024. Currently, the stock of Intelligent Bio Solutions is trading above its 10, 20, and 50-day moving averages, having experienced a surge of approximately 65% in the last month and 37% since January 1, 2024. This surge occurred on relatively low trading volume compared to its 30- and 60-day volume averages. It's important to highlight that the stock has an extremely low reported float and is trading around $4.50 per share, with a 52-week high of $49.20 per share. Furthermore, institutional investors own approximately 9.3% of Intelligent Bio Solutions shares, while insiders hold 0.3%. See Institutional Ownership Information The company disclosed that these agreements were with various institutional and accredited investors. Intelligent Bio Solutions issued a total of 2,223,333 shares of common stock, along with Series H-1 warrants for the purchase of up to 2,223,333 shares of common stock, and Series H-2 warrants for the purchase of 2,223,333 shares of common stock. The shares were priced at $4.55 each, aiming to raise approximately $10.1 million in proceeds. However, it's important to note that deductions for agent fees and other offering-related expenses will be applied. Additionally, Intelligent Bio Solutions announced that the Series H-1 warrants would have an 18-month term, while the Series H-2 warrants would be valid for 5 years. Ladenburg Thalmann & Co., Inc. serves as the exclusive agent for the private placement, expected to close by March 12, 2024. The proceeds from the offering will be allocated towards financing the company's general corporate and working capital requirements. Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content."TSR" is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. "TSR" authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. "TSR" has not been compensated to produce content related to "Any Companies" appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.Media ContactCompany Name: The Street ReportsContact Person: EditorEmail: Send EmailCountry: United StatesWebsite: http://www.thestreetreports.com
Intelligent Bio Solutions Inc. (NASDAQ: INBS) the medical technology firm, renowned for its provision of rapid, non-invasive, and intelligent testing solutions, revealed that it had executed several securities purchase agreements on March 8, 2024, and declared the conclusion of the $10.1M offering on March 12, 2024. Currently, the stock of Intelligent Bio Solutions is trading above its 10, 20, and 50-day moving averages, having experienced a surge of approximately 65% in the last month and 37% since January 1, 2024. This surge occurred on relatively low trading volume compared to its 30- and 60-day volume averages. It's important to highlight that the stock has an extremely low reported float and is trading around $4.50 per share, with a 52-week high of $49.20 per share. Furthermore, institutional investors own approximately 9.3% of Intelligent Bio Solutions shares, while insiders hold 0.3%. See Institutional Ownership Information The company disclosed that these agreements were with various institutional and accredited investors. Intelligent Bio Solutions issued a total of 2,223,333 shares of common stock, along with Series H-1 warrants for the purchase of up to 2,223,333 shares of common stock, and Series H-2 warrants for the purchase of 2,223,333 shares of common stock. The shares were priced at $4.55 each, aiming to raise approximately $10.1 million in proceeds. However, it's important to note that deductions for agent fees and other offering-related expenses will be applied. Additionally, Intelligent Bio Solutions announced that the Series H-1 warrants would have an 18-month term, while the Series H-2 warrants would be valid for 5 years. Ladenburg Thalmann & Co., Inc. serves as the exclusive agent for the private placement, expected to close by March 12, 2024. The proceeds from the offering will be allocated towards financing the company's general corporate and working capital requirements. Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content."TSR" is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. "TSR" authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. "TSR" has not been compensated to produce content related to "Any Companies" appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.Media ContactCompany Name: The Street ReportsContact Person: EditorEmail: Send EmailCountry: United StatesWebsite: http://www.thestreetreports.com
